289711-21-3

Usage

Uses

Used in Pharmaceutical Industry:
D,L-SULFORAPHANE GLUTATHIONE is used as a pharmaceutical agent for its potential therapeutic effects. It has been found to possess antioxidant, anti-inflammatory, and anti-cancer properties, making it a promising candidate for the development of new drugs targeting various diseases.
Used in Anticancer Applications:
In the field of oncology, D,L-SULFORAPHANE GLUTATHIONE is used as an anticancer agent. It has been shown to modulate several oncological signaling pathways, leading to the inhibition of tumor growth and progression. Additionally, it has demonstrated synergistic anticancer effects when combined with conventional chemotherapeutic drugs, enhancing chemo-sensitivity and efficacy in resistant cases.
Used in Nutraceutical Industry:
D,L-SULFORAPHANE GLUTATHIONE is also used in the nutraceutical industry as a dietary supplement. It is believed to provide health benefits, such as boosting the immune system, promoting detoxification, and supporting overall health.
Used in Research and Development:
In the research and development sector, D,L-SULFORAPHANE GLUTATHIONE is used as a key compound for studying the mechanisms of action and potential applications of Sulforaphane and its derivatives. This helps in the development of new drugs and therapies for various diseases, including cancer.
Used in Drug Delivery Systems:
To enhance the bioavailability and therapeutic outcomes of D,L-SULFORAPHANE GLUTATHIONE, novel drug delivery systems have been developed. These systems employ various organic and metallic nanoparticles as carriers for the compound, aiming to improve its delivery and efficacy against target cells and tissues.

InChI:InChI=1/C16H28N4O7S3/c1-30(27)7-3-2-6-18-16(28)29-9-11(14(24)19-8-13(22)23)20-12(21)5-4-10(17)15(25)26/h10-11H,2-9,17H2,1H3,(H,18,28)(H,19,24)(H,20,21)(H,22,23)(H,25,26)/t10-,11-,30?/m0/s1

Upstream product

• 4478-93-7 D,L-sulforaphane 
• 70-18-8 GLUTATHIONE 

Relevant academic research and scientific papers

Glucoraphanin and sulforaphane evolution during juice preparation from broccoli sprouts

Broccoli sprouts are considered functional food as they are naturally enriched in glucoraphanin (GR) that is the biological precursor of the anticancer compound sulforaphane (SFN). Due to its health promoting value, also broccoli sprout juice is becoming

Discovery of a crystalline sulforaphane analog with good solid-state stability and engagement of the Nrf2 pathway in vitro and in vivo

The antioxidant natural product sulforaphane (SFN) is an oil with poor aqueous and thermal stability. Recent work with SFN has sought to optimize methods of formulation for oral and topical administration. Herein we report the design of new analogs of SFN with the goal of improving stability and drug-like properties. Lead compounds were selected based on potency in a cellular screen and physicochemical properties. Among these, 12 had good aqueous solubility, permeability and long-term solid-state stability at 23 °C. Compound 12 also displayed comparable or better efficacy in cellular assays relative to SFN and had in vivo activity in a mouse cigarette smoke challenge model of acute oxidative stress.

A Comparative Assessment Study of Known Small-Molecule Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Chemical Synthesis, Binding Properties, and Cellular Activity

Inhibiting the protein-protein interaction (PPI) between the transcription factor Nrf2 and its repressor protein Keap1 has emerged as a promising strategy to target oxidative stress in diseases, including central nervous system (CNS) disorders. Numerous non-covalent small-molecule Keap1-Nrf2 PPI inhibitors have been reported to date, but many feature suboptimal physicochemical properties for permeating the blood-brain barrier, while others contain problematic structural moieties. Here, we present the first side-by-side assessment of all reported Keap1-Nrf2 PPI inhibitor classes using fluorescence polarization, thermal shift assay, and surface plasmon resonance - and further evaluate the compounds in an NQO1 induction cell assay and in counter tests for nonspecific activities. Surprisingly, half of the compounds were inactive or deviated substantially from reported activities, while we confirm the cross-assay activities for others. Through this study, we have identified the most promising Keap1-Nrf2 inhibitors that can serve as pharmacological probes or starting points for developing CNS-active Keap1 inhibitors.